TCM
GPCR icon

TCG Crossover Management’s Structure Therapeutics GPCR Stock Holding History

TCG Crossover Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140,411
Closed -$6.77M – 57
2026
Q1 		$6.77M Sell
140,411
-780,446
-85% -$53.4M 0.19% 44
2025
Q4 		$64M Sell
920,857
-142,143
-13% -$5.8M 2.12% 15
2025
Q3 		$29.8M Hold
1,063,000
– – 1.46% 20
2025
Q2 		$22M Hold
1,063,000
– – 2.52% 19
2025
Q1 		$18.4M Hold
1,063,000
– – 2.51% 18
2024
Q4 		$28.8M Hold
1,063,000
– – 2.82% 15
2024
Q3 		$46.7M Buy
1,063,000
+368,453
+53% +$14.2M 3.95% 11
2024
Q2 		$27.3M Sell
694,547
-903,874
-57% -$37.1M 2.84% 14
2024
Q1 		$68.5M Sell
1,598,421
-511,163
-24% -$21.6M 5.42% 5
2023
Q4 		$86M Buy
2,109,584
+606,837
+40% +$34.8M 9.54% 1
2023
Q3 		$75.8M Buy
1,502,747
+1,152,747
+329% +$37.1M 11.16% 1
2023
Q2 		$14.5M Hold
350,000
– – 2.39% 13
2023
Q1 		$8.33M Buy
+350,000
New +$8.22M 1.62% 17

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

TCG Crossover Management's GPCR Position: Q2 2026 in Review

TCG Crossover Management sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 140,411 shares — an estimated $6.77M sold.

TCG Crossover Management first reported a position in GPCR in Q1 2023 and held it in 13 quarters. The position peaked at $86M in Q4 2023. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • TCG Crossover Management reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TCG Crossover Management sold 140,411 Structure Therapeutics shares in Q2 2026, an estimated $6.77M.
  • TCG Crossover Management first reported a position in Structure Therapeutics in Q1 2023 and held it in 13 quarters.
  • TCG Crossover Management's Structure Therapeutics position peaked at $86M in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.